1473 related articles for article (PubMed ID: 8440338)
1. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
3. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
5. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
[TBL] [Abstract][Full Text] [Related]
8. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
[TBL] [Abstract][Full Text] [Related]
9. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
[TBL] [Abstract][Full Text] [Related]
10. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
12. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease.
Klingemann HG; Wilkie-Boyd K; Rubin A; Onetto N; Nantel SH; Barnett MJ; Reece DE; Shepherd JD; Phillips GL
Biotechnol Ther; 1994; 5(1-2):1-13. PubMed ID: 7703829
[TBL] [Abstract][Full Text] [Related]
14. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor.
Haas R; Ho AD; Bredthauer U; Cayeux S; Egerer G; Knauf W; Hunstein W
Exp Hematol; 1990 Feb; 18(2):94-8. PubMed ID: 1968009
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
Sallerfors B; Olofsson T; Lenhoff S
Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
[TBL] [Abstract][Full Text] [Related]
16. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
[TBL] [Abstract][Full Text] [Related]
17. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors.
Ottmann OG; Abboud M; Welte K; Souza LM; Pelus LM
Exp Hematol; 1989 Feb; 17(2):191-7. PubMed ID: 2463933
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
